RESUMO
Introduction: Pseudomonas aeruginosa is known for its ability to form biofilms, which are dependent on the production of exopolysaccharides. During chronic colonization of the airway and biofilm formation, P. aeruginosa converts to a mucoid phenotype, indicating production of the exopolysaccharide alginate. The mucoid phenotype promotes resistance to phagocytic killing, but the mechanism has not been established. Methods and Results: To better understand the mechanism of phagocytic evasion conferred by alginate production, Human (THP-1) and murine (MH-S) macrophage cell lines were used to determine the effects of alginate production on macrophage binding, signaling and phagocytosis. Phagocytosis assays using mucoid clinical isolate FRD1 and its non-mucoid algD mutant showed that alginate production inhibited opsonic and non-opsonic phagocytosis, but exogenous alginate was not protective. Alginate caused a decrease in binding to murine macrophages. Blocking antibodies to CD11b and CD14 showed that these receptors were important for phagocytosis and were blocked by alginate. Furthermore, alginate production decreased the activation of signaling pathways required for phagocytosis. Mucoid and non-mucoid bacteria induced similar levels of MIP-2 from murine macrophages. Discussion: This study demonstrated for the first time that alginate on the bacterial surface inhibits receptor-ligand interactions important for phagocytosis. Our data suggest that there is a selection for alginate conversion that blocks the earliest steps in phagocytosis, leading to persistence during chronic pulmonary infections.
Assuntos
Infecções por Pseudomonas , Pseudomonas aeruginosa , Camundongos , Animais , Humanos , Pseudomonas aeruginosa/genética , Fagocitose , Macrófagos , Biofilmes , Linhagem Celular , Infecções por Pseudomonas/microbiologiaRESUMO
BACKGROUND: Splenic artery angioembolization (SAE) is increasingly being used as an adjunct to nonoperative management for stable patients with blunt splenic injury (BSI). However, little is known about splenic immunocompetence after SAE. This study aims at assessing splenic immunocompetence after SAE for BSI. METHODS: Peripheral blood was obtained from BSI patients (n = 8) who had SAE >6 months prior. Splenic immunocompetence was assessed by isolating mononuclear cells and incubating with CD4 and CD45RA and CD45RO antibody to analyze the proportion of T-cells expressing CD4 receptor, or coexpressing CD4 and either CD45RA or CD45RO receptors. Cells were counted by fluorescence-activated cell sorting and compared with trauma patients that had splenectomy for BSI also >6 months prior (n = 4, negative controls) and normal healthy volunteers with intact spleens (n = 4, positive controls). RESULTS: The test was discriminatory for the asplenic state. %CD4 cells were significantly lower in splenectomized patients (16 ± 1) versus normal (40 ± 2), p < 0.05. This was due to significant decrease (8 ± 2 vs. 26 ± 4, p < 0.05) in %CD4CD45RA cells whereas the proportion of CD4CD45RO cells were maintained similar to normal. SAE patients had values (CD4, 36 ± 2, and CD4CD45RA, 24 ± 2) comparable to normal (p > 0.05) and significantly higher than splenectomized patients (p < 0.05). When the SAE group was subdivided into main (total, n = 4) and branch vessel (partial, n = 4) SAE, results were the same for both types of SAE. CONCLUSION: Splenic immune function, measured by T-cell subset, generated only in the presence of an immunocompetent spleen, is preserved after SAE for BSI, main or partial.
Assuntos
Embolização Terapêutica/métodos , Imunocompetência , Preservação Biológica/métodos , Baço/imunologia , Artéria Esplênica/diagnóstico por imagem , Subpopulações de Linfócitos T/imunologia , Ferimentos não Penetrantes/terapia , Adolescente , Adulto , Idoso , Angiografia , Feminino , Humanos , Imunidade Celular , Escala de Gravidade do Ferimento , Masculino , Pessoa de Meia-Idade , Período Pós-Operatório , Baço/irrigação sanguínea , Baço/lesões , Esplenectomia , Tomografia Computadorizada por Raios X , Resultado do Tratamento , Ferimentos não Penetrantes/diagnóstico por imagem , Ferimentos não Penetrantes/imunologia , Adulto JovemRESUMO
It is well established that loss of a growth inhibitory response to transforming growth factor-beta (TGF-beta) is a common feature of epithelial cancers including esophageal cancer. However, the molecular basis for the abrogation of this key homeostatic mechanism is poorly understood. In esophageal cancer cell lines that are resistant to TGF-beta-induced growth inhibition, TGF-beta also fails to decrease transcription of c-myc despite the presence of functional signaling components. Consequently, to gain a better understanding of the mechanisms leading to resistance to TGF-beta-induced growth arrest, the basis for the inability to decrease c-myc transcription was investigated. Regardless of sensitivity to TGF-beta-induced growth arrest, TGF-beta enhanced the ability of Smad3-protein complexes to bind c-myc regulatory elements. However, in a growth inhibition-resistant esophageal cancer cell line, the Smad3-protein complexes contained the SnoN oncoprotein. Furthermore, in esophageal cancer cell lines that are resistant to TGF-beta-induced growth arrest, TGF-beta does not cause degradation of SnoN. Analyses of the effect of modulating SnoN expression in both growth inhibition-sensitive and growth inhibition-resistant cell lines showed that degradation of SnoN is a prerequisite for both TGF-beta-induced repression of c-myc transcription and growth arrest. The data indicate that SnoN-Smad3 complexes do not cause repression of c-myc transcription but rather prevent functionality of active repressor complexes. Thus, these studies reveal a novel mechanism for resistance to TGF-beta-induced growth inhibition in esophageal cancer, namely the failure to degrade SnoN. In addition, they show that SnoN can block TGF-beta repression of gene transcription.
Assuntos
Neoplasias Esofágicas/metabolismo , Neoplasias Esofágicas/patologia , Proteínas Proto-Oncogênicas/metabolismo , Fator de Crescimento Transformador beta/farmacologia , Adenocarcinoma/metabolismo , Adenocarcinoma/patologia , Carcinoma de Células Escamosas/metabolismo , Carcinoma de Células Escamosas/patologia , Processos de Crescimento Celular/efeitos dos fármacos , Processos de Crescimento Celular/fisiologia , Linhagem Celular Tumoral , Proteínas de Ligação a DNA/metabolismo , Neoplasias Esofágicas/genética , Genes myc , Humanos , Peptídeos e Proteínas de Sinalização Intracelular , Proteínas Proto-Oncogênicas/biossíntese , Proteínas Proto-Oncogênicas c-myc/biossíntese , Proteínas Proto-Oncogênicas c-myc/genética , Proteína Smad3 , Transativadores/metabolismo , Transcrição Gênica , Fator de Crescimento Transformador beta/antagonistas & inibidoresAssuntos
Subpopulações de Linfócitos B/metabolismo , Imunoglobulina A/história , Lipopolissacarídeos/história , Fator de Crescimento Transformador beta/história , Animais , Células Cultivadas , Feminino , Rearranjo Gênico do Linfócito B , História do Século XX , Imunoglobulina A/biossíntese , Imunoglobulina A/genética , Switching de Imunoglobulina , Lipopolissacarídeos/fisiologia , Camundongos , Camundongos Endogâmicos BALB C , Recombinação Genética , Fator de Crescimento Transformador beta/fisiologiaRESUMO
The role of the transforming growth factor beta (TGFbeta) pathway in the development and progression of esophageal cancers is poorly understood. As an initial step in clarification of this issue, the functional status of the TGFbeta pathway was evaluated in a panel of esophageal cancer derived cell lines. Both adenocarcinoma and squamous cell carcinoma derived lines were represented. Although the TGFbeta pathway was intact and functional in four of the five cell lines, only one of them was growth inhibited by TGFbeta. In one cell line, the loss of a growth inhibitory response to TGFbeta could be explained by decreased expression of Smad 4 and a general inability to activate TGFbeta responsive promoters. In the other three cell lines, TGFbeta was able to activate transcription of TGFbeta responsive promoters, but unable to downregulate transcription of c-myc. Taken together these findings indicate that a selective loss in the ability of TGFbeta to regulate expression of a key component of the growth inhibitory pathway may contribute to the poor prognosis of esophageal cancers.
Assuntos
Neoplasias Esofágicas/tratamento farmacológico , Fator de Crescimento Transformador beta/farmacologia , Regulação para Baixo , Neoplasias Esofágicas/metabolismo , Neoplasias Esofágicas/patologia , Genes myc , Humanos , Células Tumorais CultivadasRESUMO
Transforming growth factor (TGF)-beta has profound effects on epithelial cell differentiation and is capable of modulating the response to exposure to ionizing radiation. We recently reported that TGF-beta downregulates c-myc mRNA expression and inhibits the growth of OE-33 esophageal carcinoma cells in vitro. These studies investigate the role of TGF-beta in the in vitro radiation response of OE-33 and four other human esophageal cancer cell lines. TGF-beta enhanced radioresistance of OE-33 cells, but did not affect the radiosensitivity of either of the two other adenocarcinoma cell lines BIC1 and SEG1 or of squamous carcinomas KYSE and OE-21. The TGF-beta enhanced radioresistance phenotype was associated with induced G0/G1 cell cycle arrest and upregulation of the G1 cyclin-dependent kinase inhibitor p27kip1 as well as downregulation of c-myc protein expression. Comparison of the relative radiosensitivities of untreated cells suggested that OE-33 (SF2 = 0.71) cells were inherently more radioresistant than BIC1 or SEG1 cells (SF2 = 0.6 and 0.56, respectively). Conditioned medium obtained from unirradiated OE-33 cells enhanced radioresistance compared with fresh medium. This enhancement was abrogated by preincubation of conditioned medium with a neutralizing anti-TGF-beta antibody suggesting endogenous TGF-beta production by OE-33 cells. Enzyme-linked immunoabsorbent assays revealed that exposure to ionizing radiation increased TGF-beta production in all five cell lines. These results suggest that TGF-beta acts as an endogenous, radiation-inducible radioresistance factor in OE-33 esophageal carcinoma cells.
Assuntos
Adenocarcinoma/radioterapia , Neoplasias Esofágicas/radioterapia , Tolerância a Radiação , Fator de Crescimento Transformador beta/metabolismo , Adenocarcinoma/patologia , Carcinoma/radioterapia , Carcinoma de Células Escamosas/patologia , Proteínas de Ciclo Celular/metabolismo , Diferenciação Celular , Linhagem Celular Tumoral , Meios de Cultivo Condicionados/farmacologia , Inibidor de Quinase Dependente de Ciclina p27 , Relação Dose-Resposta a Droga , Relação Dose-Resposta à Radiação , Regulação para Baixo , Ensaio de Imunoadsorção Enzimática , Citometria de Fluxo , Fase G1 , Humanos , Fenótipo , Proteínas Proto-Oncogênicas c-myc/metabolismo , RNA Mensageiro/metabolismo , Radiação Ionizante , Proteínas Supressoras de Tumor/metabolismoRESUMO
Light is used to release a drug from a cell impermeable small molecule, uncloaking its cytotoxic effect on cancer cells.
Assuntos
Preparações de Ação Retardada , Doxorrubicina/química , Luz , Modelos Biológicos , Naftalenossulfonatos/química , Antineoplásicos/química , Linhagem Celular , Preparações de Ação Retardada/química , Citometria de Fluxo , Humanos , Estrutura Molecular , Permeabilidade , Preparações Farmacêuticas/químicaRESUMO
Lysophosphatidic acid (LPA) is a multifunctional intercellular phospholipid mediator present in blood and other biological fluids. In cancer cells, LPA stimulates expression or activity of inflammatory cytokines, angiogenic factors, matrix metalloproteinases, and other oncogenic proteins. In this study, we showed that LPA upregulated expression of the cyclin-dependent kinase inhibitor p21(Waf1) in TGFß-sensitive breast and ovarian cancer cells, but not in TGFß-resistant ones. We examined the possibility that LPA-induced p21 might contribute to the cytostatic response to TGFß. In serum-free conditions, TGFß alone induced p21 expression weakly in TGFß-sensitive cells. Serum or serum-borne LPA cooperated with TGFß to elicit the maximal p21 induction. LPA stimulated p21 via LPA(1) and LPA(2) receptors and Erk-dependent activation of the CCAAT/enhancer binding protein beta transcription factor independent of p53. Loss or gain of p21 expression led to a shift between TGFß-sensitive and -resistant phenotypes in breast and ovarian cancer cells, indicating that p21 is a key determinant of the growth inhibitory activity of TGFß. Our results reveal a novel cross-talk between LPA and TGFß that underlies TGFß-sensitive and -resistant phenotypes of breast and ovarian cancer cells.
Assuntos
Neoplasias da Mama/tratamento farmacológico , Inibidor de Quinase Dependente de Ciclina p21/biossíntese , Lisofosfolipídeos/farmacologia , Neoplasias Ovarianas/tratamento farmacológico , Fator de Crescimento Transformador beta/farmacologia , Neoplasias da Mama/metabolismo , Linhagem Celular Tumoral , Sinergismo Farmacológico , Feminino , Humanos , Imuno-Histoquímica , Neoplasias Ovarianas/metabolismo , Fosforilação , Fator de Crescimento Transformador beta/metabolismoRESUMO
Tumors frequently contain hypoxic regions that result from a shortage of oxygen due to poorly organized tumor vasculature. Cancer cells in these areas are resistant to radiation- and chemotherapy, limiting the treatment efficacy. Macrophages have inherent hypoxia-targeting ability and hold great advantages for targeted delivery of anticancer therapeutics to cancer cells in hypoxic areas. However, most anticancer drugs cannot be directly loaded into macrophages because of their toxicity. In this work, we designed a novel drug delivery vehicle by hybridizing macrophages with nanoparticles through cell surface modification. Nanoparticles immobilized on the cell surface provide numerous new sites for anticancer drug loading, hence potentially minimizing the toxic effect of anticancer drugs on the viability and hypoxia-targeting ability of the macrophage vehicles. In particular, quantum dots and 5-(aminoacetamido) fluorescein-labeled polyamidoamine dendrimer G4.5, both of which were coated with amine-derivatized polyethylene glycol, were immobilized to the sodium periodate-treated surface of RAW264.7 macrophages through a transient Schiff base linkage. Further, a reducing agent, sodium cyanoborohydride, was applied to reduce Schiff bases to stable secondary amine linkages. The distribution of nanoparticles on the cell surface was confirmed by fluorescence imaging, and it was found to be dependent on the stability of the linkages coupling nanoparticles to the cell surface.
Assuntos
Antineoplásicos/química , Hipóxia Celular/efeitos dos fármacos , Hipóxia Celular/fisiologia , Membrana Celular/química , Macrófagos/química , Nanocápsulas/química , Animais , Antineoplásicos/administração & dosagem , Linhagem Celular , Macrófagos/efeitos dos fármacos , Camundongos , Nanocápsulas/ultraestruturaRESUMO
Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid that mediates a wide array of biologic effects through its interaction with a family of five G protein-coupled receptors. Cytokines and growth factors interact with this signaling pathway in a variety of ways, including both activation and regulation of the expression of the enzymes that regulate synthesis and degradation of S1P. Not only do many growth factors and cytokines stimulate S1P production, leading to transactivation of S1P receptors, ligation of S1P receptors by S1P can also transactivate growth factor tyrosine kinase receptors and stimulate growth factor and cytokine signaling cascades. This review discusses the mechanisms involved in cross-talk between S1P, cytokines, and growth factors and the impact of that cross-talk on cell signaling and cell biology.
Assuntos
Citocinas/metabolismo , Peptídeos e Proteínas de Sinalização Intercelular/metabolismo , Lisofosfolipídeos/metabolismo , Receptor Cross-Talk , Transdução de Sinais , Esfingosina/análogos & derivados , Animais , Humanos , Ligação Proteica , Esfingosina/metabolismoRESUMO
Transforming growth factor beta (TGFbeta) plays a dual role in oncogenesis, acting as both a tumor suppressor and a tumor promoter. These disparate processes of suppression and promotion are mediated primarily by Smad and non-Smad signaling, respectively. A central issue in understanding the role of TGFbeta in the progression of epithelial cancers is the elucidation of the mechanisms underlying activation of non-Smad signaling cascades. Because the potent lipid mediator sphingosine-1-phosphate (S1P) has been shown to transactivate the TGFbeta receptor and activate Smad3, we examined its role in TGFbeta activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and promotion of migration and invasion of esophageal cancer cells. Both S1P and TGFbeta activate ERK1/2, but only TGFbeta activates Smad3. Both ligands promoted ERK1/2-dependent migration and invasion. Furthermore, TGFbeta rapidly increased S1P, which was required for TGFbeta-induced ERK1/2 activation, as well as migration and invasion, since downregulation of sphingosine kinases, the enzymes that produce S1P, inhibited these responses. Finally, our data demonstrate that TGFbeta activation of ERK1/2, as well as induction of migration and invasion, is mediated at least in part by ligation of the S1P receptor, S1PR2. Thus, these studies provide the first evidence that TGFbeta activation of sphingosine kinases and formation of S1P contribute to non-Smad signaling and could be important for progression of esophageal cancer.